Published in final edited form as:

J Genet Syndr Gene Ther. ; 1: 1–9. doi:10.4172/2157-7412.S1-009.

Liver-Directed Adeno-Associated Viral Gene Therapy for Hemophilia

David M. Markusic and Roland W Herzog*

Department of Pediatrics, University of Florida, Gainesville, FL 32610, USA

Abstract

Hemophilia A and B are monogenic bleeding disorders resulting from loss of functional coagulation factors VIII or IX, respectively. Prophylactic treatment requires frequent intravenous injections of exogenous factor VIII (F.VIII) or factor IX (F.IX), due to the short half-life of both factors. Hemophilia patients are at risk of developing neutralizing antibodies to F.VIII (~25–30%) or F.IX (~2–4%), which require the use of expensive bypass agents and immune tolerance induction protocols. Viral vector mediated liver gene transfer of F.VIII or F.IX offers an alternative treatment for hemophilia with easily defined clinical endpoints and no need for strict regulation of coagulation factor expression, as both proteins circulate as inactive zymogens. Adeno-associated viral (AAV) vectors are derived from a non-pathogenic human virus that efficiently transduce non-dividing cells, such as hepatocytes, and provide stable transgene expression. *In vivo* liver gene transfer of AAV-F.VIII and -F.IX vectors has restored hemostasis in murine and canine hemophilia models long-term, and has also been shown to induce immune tolerance. Consequently, two Phase I/II clinical trials have been conducted, based on hepatic AAV-FIX gene transfer to patients with severe hemophilia B. The first trial, utilizing serotype 2, demonstrated transient correction, which was limited by a cellular immune response against the viral capsid. However, sustained therapeutic expression has been achieved in a second trial, using AAV8 for expression of a codon-optimized F.IX transgene. Translation of F.VIII gene transfer studies into the clinic may require additional optimization of gene transfer and vector to effectively express the larger cDNA of F.VIII.

Keywords

Hemophilia; Adeno-associated virus; AAV; Liver; Factor VIII; Factor IX; Gene transfer

Hemophilia

Hemophilia is a bleeding disorder resulting from the loss of functional coagulation factors VIII (Hemophilia A) and IX (Hemophilia B). The severity and frequency of bleeding episodes is related to residual coagulation factor activity, patients with less than 1% activity often suffer from spontaneous bleeds. Bleeding episodes are treated in the clinic with intravascular (IV) administration of exogenous Factor VIII or IX from plasma concentrates or recombinant protein. Clinical data from treated patients show that maintaining coagulation factor levels above 1% has a significant impact on the frequency of spontaneous bleeding and above 5% results in the elimination of spontaneous bleeds. Unfortunately, a

Copyright: © 2012 Markusic DM, et al.

*Corresponding author: Roland Herzog, Department of Pediatrics, University of Florida, Cancer and Genetics Research Center, 2033 Mowry Road, Gainesville, FL 32610, USA, Tel: 352-273-8149; Fax: 352-273-8342; rherzog@ufl.edu.

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

subset of patients (hemophilia A ~25–30%, hemophilia B ~2–4%) is at risk for developing neutralizing antibodies to the exogenously administered coagulation factors. These inhibitors abolish therapeutic benefit and require expensive long-term immune tolerance induction (ITI) protocols for the eradication of inhibitors. Prophylactic treatment of hemophilia patients requires frequent IV injections to maintain steady state levels of the respective coagulation factor, which presents a burden on the patient and is quite expensive. Novel factor products with longer half-life in circulation are currently being developed. Since the liver is the natural site of F.VIII and F.IX synthesis, liver gene transfer of a functional copy of F.VIII or F.IX offers an alternative treatment approach with the potential to provide stable therapeutic F.VIII or F.IX expression from a single injection. Adeno-associated virus (AAV) vectors have shown a promising platform for long-term liver gene transfer.

Adeno-Associated Virus (AAV)

AAV is a non-pathogenic single stranded DNA parvovirus with a genome size of approximately 4.7kb. Serotypes with distinct tissue tropisms have been isolated from multiple vertebrate species, including humans [1]. Viral vectors derived from AAV are devoid of viral genes and instead contain an expression cassette for the gene of interest, which is limited to ~5kb in length. Several factors make AAV vectors ideally suited for liver gene transfer including the ability to infect non-dividing cells such as hepatocytes, low immunogenicity [2–4], and the persistence of vector genomes as episomal concatamers [5,6].

The AAV2 serotype was the first serotype developed as a vector for gene transfer and has been tested extensively in both small and large animals and in two human clinical trials for muscle [7] and liver gene transfer of hF.IX [8]. Despite efficient infection of murine liver, AAV genomes detected in almost 100% of hepatocytes, only roughly 5% of murine hepatocytes expressed transgene [9–11]. Several steps in AAV2 vector infection have been identified that restrict murine liver gene transfer. Since AAV vectors have a single stranded DNA (ssDNA) genome, expression of the gene of interest requires conversion to double stranded DNA (dsDNA), this step acts as a limiting step in transgene expression [12,13]. A cellular protein, FKBP52, was shown to interact with the AAV genome, when phosphorylated, and prevent conversion to dsDNA [14]. Two distinct approaches were taken to bypass this block. The first focused on preventing the phosphorylation of the FKBP52 protein by pharmacological inhibition of phosphorylation [15] and forced expression of phosphatases TCT-PTP [16] and PP5 [17] both of which led to significant increases of *in vivo* transgene expression. Toxicity studies from over-expression of TCT-PTP or PP5 need to be evaluated in large animal models before consideration for human use. The second approach generated an AAV genome that was self-complementary, spontaneously forming into dsDNA ready for transgene expression, thus completely bypassing the need for second strand synthesis [18–20]. One drawback of scAAV vectors is that they reduce an already limited packaging capacity of AAV vectors in half thus excluding large transgenes, such as F.VIII. AAV2 viral particle intracellular trafficking and uncoating also impact efficient gene transfer [21,22]. For AAV2, a large fraction of viral particles are retained in the cytoplasm upon cell entry. The capsid is phosphorylated by EGFR-PTK, which signals for ubiquitination and targeting of the viral particle to the proteasome [23]. Mutation of surfaced exposed tyrosine residues to phenylalanine, in particular residues 444, 500, and 730 resulted individually in improved gene transfer of murine liver [24] and when combined further enhanced gene expression [25]. Of the currently identified serotypes, AAV8, isolated from non-human primates [26], has the highest level of liver gene transfer in mice [27,28]. AAV8 serotype vectors have faster viral uncoating compared to AAV2 where it is believed to allow for the pairing of plus and minus strand vector genomes into stable biologically active

double stranded genomes bypassing the block on second strand synthesis observed with AAV2 [26,29].

Hepatic Gene Transfer in Animal Models of Hemophilia

Since the coding for F.IX is ~1.4 kb in length, fitting well into an AAV vector genome, and since expression of F.IX is often more efficient than that of F.VIII, the majority of pre-clinical liver gene transfer studies (and all clinical trials thus far) with AAV vectors has been conducted for hemophilia B. F.IX protein undergoes extensive post-translational modifications before being secreted and since it is normally synthesized in the liver all the cellular machinery is in place for production of mature F.IX protein. As F.IX protein circulates as an inactive zymogen, there is little need for strict regulation allowing the use of strong liver specific promoters to drive gene expression. The generation of mice deficient for murine factor IX [30–32] and two spontaneous canine hemophilia B colonies [33,34] has allowed for extensive testing of safety and efficacy of AAV liver directed F.IX gene transfer.

Snyder et al. first reported the *in vivo* delivery of an AAV2 vector expressing hF.IX from a MuLV LTR promoter/enhancer (MFG) to the liver of wild type C57BL/6 mice via the portal vein. The vector injected mice had long-term hF.IX expression (up to nine months) with no indication of liver toxicity and infiltration of immune cells [9]. Stable hF.IX expression was also obtained by Nakai et al. following portal vein delivery in C57BL/6 mice of an AAV2 vector expressing hF.IX from the EF1 α promoter for a duration of six months [35]. Based on these initial studies, Snyder et al. administered AAV2 MFGhF.IX vector to hemophilia B mice and a AAV2 MFG-cF.IX vector hemophilia B dogs via the portal vein resulting in long-term correction in both animal models [36]. In parallel, Wang et al. demonstrated long-term correction in hemophilia B mice [37] and dogs [38] using an AAV2 vector expressing canine F.IX(cF.IX) from a liver specific promoter construct. Mount et al. demonstrated sustained correction in hemophilia B dogs with a null mutation, which have a higher risk for developing inhibitors, following liver directed gene transfer of an AAV2 vector expressing cF.IX from an ApoE/hAAT liver specific promoter [39] which was shown at least 8 years following gene transfer [40].

A major concern for AAV gene transfer of hF.IX to human patients is the risk of inducing an immune response against hF.IX protein that would render patients unresponsive to exogenous F.IX protein therapy. In immune competent mice, the immune responses to hF.IX expressed from an AAV2 vector is dependent on the route of delivery and the underlying F9 mutation [41,42]. All mice receiving an intramuscular (IM) injection of an AAV2 hF.IX vector generated inhibitory antibodies to hF.IX protein, while with intravascular (IV) and portal vein deliver the majority of animals remained free from inhibitors. Based on these observations and previous examples of the tolerizing nature of liver expressed proteins [43], Mingozzi et al. designed experiments showing induction of tolerance to hF.IX in four different strains of mice using an AAV2 vector with an ubiquitous EF1 α promoter or a liver-specific ApoE enhancer/ α_1 -antitrypsin (ApoE/hAAT) promoter [44]. The rate of tolerance induction was shown to be associated with the levels of expressed F.IX protein. CD4⁺ T cells from vector treated mice failed to proliferate *in vitro* following F.IX protein stimulation. Additionally, adoptive transfer of total splenocytes or CD4⁺ lymphocytes but not CD4-depleted splenocytes from vector treated mice into naïve mice suppressed F.IX specific antibody production upon subsequent immunization, demonstrating active suppression by CD4⁺ T cells as part of the tolerance mechanism. In addition, tolerance induction failed in Fas-deficient mice, suggesting a requirement for activation induced cell death [45]. A later study by Dobrzynski et al. found that hepatic-derived antigen expressed from an AAV vector induced several changes to the transgene product-

specific CD4⁺ T cell population, which included deletion, and induction of an anergic phenotype and enrichment for CD4⁺CD25⁺ Treg in the remaining cells [46]. More recent studies dissected the immune regulatory aspect further and found that hepatic viral gene transfer results in TGF- β dependent induction of CD4⁺CD25⁺ Treg, which are required for tolerance to the transgene product and capable of suppressing antibody and T cell responses. A regulatory response in the liver and expression of the suppressive cytokine IL-10 is required to prevent CD8⁺ T cell responses against transduced hepatocytes [45,47–51]. These findings are further reviewed elsewhere [43,52–54].

AAV2 Hepatic Gene Transfer Clinical Trial

Based on correction of bleeding diathesis and absence of the induction of inhibitors in both small and large models for hemophilia B by an AAV2-ApoE/hAAT-hF.IX vector and safety and persistence of an intramuscular AAV2 hF.IX clinical trial [7,55], a phase I/II clinical trial was initiated [8]. Although AAV is non-pathogenic, natural infection in humans occur with a more immunogenic helper virus, such as adenovirus, which can activate immune responses against AAV, such as the generation of neutralizing antibodies (NAB) against the viral capsid protein [56–58]. These capsid NABs have been shown to effectively block *in vivo* gene transfer to murine, nonhuman primate, and human livers at low titers [8,59–61]. A wide range of NAB titers against AAV serotypes in humans have been reported all, showing that NAB against AAV2 are the most prevalent [62–64]. Therefore, patients enrolled in the clinical trial were screened for NAB titer against AAV2 with those with a NAB titer > 1:20 being excluded from the trial.

Subjects were enrolled in three dose cohorts (8×10^{10} , 4×10^{11} , and 2×10^{12} vg/kg) and injected in the hepatic artery with the AAV2 ApoE/hAAT hF.IX vector. In the two lower dose cohorts, circulating F.IX levels remained less than 1%, with no sign of liver toxicity in the first four treated subjects (A–D). Subject E in the highest dose cohort had transient therapeutic expression of F.IX above 11% of normal that declined to baseline levels coinciding with a self-resolving rise in liver transaminase levels. Subject F (also in the high dose cohort, with a NAB titer of 1:17 against AAV2) had no long-term increase in circulating F.IX protein and showed no signs of liver damage, underscoring the impact of low NAB titers on efficient liver gene transfer and suggesting that the observed liver toxicity requires viral entry into hepatocytes. An additional subject G was enrolled in the mid dose cohort of 4×10^{11} vg/kg and had a mild transient rise in liver transaminases with F.IX levels remaining < 1%. Lymphocytes collected pre and post vector administration in subject G were used to assess T cell responses to vector capsid and F.IX protein. Surprisingly, an ELISPOT assay using peptide pools for AAV2 capsid and F.IX proteins showed expansion of AAV2 capsid-specific but not F.IX-specific CD8 T cells [8,65]. Studies conducted in control human subjects revealed the existence of capsid specific memory CD8 T cells that could be reactivated following exposure to AAV2 and other AAV serotypes, such as AAV8 [65]. Human hepatocytes infected with a similar AAV2 vector used in the clinical trial were capable of processing and presenting the capsid epitope on MHC I molecules and were lysed by capsid specific CD8⁺ T cells [66]. Although the evidence suggested that a capsid T cell response resulted in destruction of F.IX expressing hepatocytes, no previous studies in animal models predicted this response [67]. Repeated attempts to mimic the response observed in the clinical trial in mice [68–74] and nonhuman primates (which, unlike mice, are naturally infected with AAV) have been unsuccessful [75]. In a recent study, Li et al. compared AAV capsid specific T cells found in naturally infected humans and rhesus macaques [76]. While rhesus macaques had detectable capsid specific CD4⁺ and CD8⁺ T cells, there were profound differences in the frequency and functionality of these capsid specific T cells compared to humans. These results may explain why the nonhuman primate model could not recapitulate the capsid immune response observed in the human clinical

trial. Lack of animal studies that could reproduce the transaminitis observed in the human AAV2 F.IX trial has prompted alternative theories to explain the loss of F.IX expression. Two prominent theories are the carry over of rep/cap plasmid and the reading of an alternative reading in the F.IX cassette [77]. The former theory has been evaluated and seems unlikely to be a contributing factor [78], while the latter is also not supported by animal studies.

Based on strong evidence of a capsid CD8⁺ T cell response being responsible for loss of F.IX expression the AAV2 F.IX clinical trial has been modified to include immune suppression (IS) prior to and following vector administration, until vector particles are degraded and cleared from hepatocytes, to prevent reactivation of CD8⁺ T cells. Studies performed in nonhuman primates showed that transient IS does not alter AAV transduction [79,80]. But, careful selection of suppression agents is warranted. Although MMF (Mycophenolate Mofetil) and sirolimus were well tolerated, addition of a third agent daclizumab, an anti IL-2 receptor antibody, resulted in the generation of inhibitors against F.IX, likely because of depletion of Treg [80]. Along this arm, a recent study investigated the use of a clinically approved proteasome inhibitor, bortezomib, to prevent AAV2 capsid peptide presentation on MHC I molecules. Finn et al. showed a dose dependent effect of bortezomib treated hepatocytes on capsid antigen presentation following AAV2 transduction [81]. Such a therapy in combination with IS may further reduce the risk of capsid antigen presentation.

Data from the initial AAV2 F.IX liver gene transfer clinical trial suggest that vector doses 4×10^{11} vg/kg and lower are well tolerated with only one subject G (with the lowest pre-treatment NAB titer within the dose cohort) with a mild liver toxicity that was asymptomatic and spontaneously resolved [8]. With this target in mind, enhancing F.IX expression at least 10 fold could potentially provide long-term therapeutic F.IX levels in the absence of liver toxicity. *In vivo* delivery of bortezomib has been shown to increase F.IX transgene expression in mice [73,81,82] and may have a dual function in reducing the risk of activating capsid CD8⁺ T cells. In murine hemophilia B models the use of alternative AAV serotypes, such as AAV2 tyrosine mutant vectors [24,25] and AAV8 [83] resulted in F.IX expression levels in excess of 10 fold over AAV2. Studies are ongoing to assess if the AAV2 tyrosine mutant vectors also enhance expression in a large animal canine hemophilia B model.

AAV8 Hepatic Gene Transfer Clinical Trial

Nathwani et al. selected an AAV vector that contained three different elements known to individually enhance liver gene expression in mice namely, an AAV8 capsid serotype [28], a scAAV genome with an optimized liver specific promoter (LP-1), and a codon optimized hF.IX gene (scAAV8 LP-1 cohF.IX). Their scAAV8 LP-1 cohF.IX vector led to substantially higher F.IX levels compared to control vectors in hemophilia B mice and nonhuman primates [84] and importantly provided similar therapeutic expression levels from peripheral vein delivery [85]. Long-term follow-up (~5 years) of nonhuman primates treated with the scAAV8 LP-1 cohF.IX vector showed sustained therapeutic expression of F.IX, absence of capsid specific CD8⁺ T cells, and no indications of toxicity [86]. Therapeutic and safety data obtained from nonhuman primate studies prompted initiation of a second clinical trial of AAV liver gene transfer for hemophilia B using the scAAV8 LP-1 cohF.IX vector.

As with the AAV2 F.IX trial subjects with existing or previous F.IX inhibitors were excluded. Additionally, subjects with F.IX mutations, deletions, or inversions associated with increased risk of inhibitors were excluded, as well as any subjects testing positive for NABs to AAV8 based on a passive transfer assay in immune deficient mice. Subjects in the

scAAV8 LP-1 cohF.IX trial were administered vector by the peripheral vein in three escalating dose cohorts (2×10^{11} vg/kg, 6×10^{11} vg/kg, and 2×10^{12} vg/kg). As reported by Nathwani et al. six subjects have been treated and are stably expressing F.IX protein in the range of 2–11% normal [87]. Both subjects in the low dose cohort had detectable F.IX levels ~2% normal with no indication of an activated capsid specific T cell response. In the mid dose cohort one of two subjects (Subject 3) had pre-existing NAB to AAV8 resulting in lower F.IX expression immediately following gene transfer that later stabilized to 1–3% normal levels. The second subject had peak levels of 4% that remained stable up to 3 months and then declined to 2–3% for unknown reasons. Capsid specific CD4 and CD8 T cells were detected, with no indication of liver damage or changes in F.IX expression levels. Both subjects in the high dose cohort had peak F.IX expression of 8–12% normal, but Subject 5 suffered from a grade 3 transaminitis, with concomitant increase in capsid specific T cells, that were ablated with prednisolone treatment, resulting in a drop in F.IX levels to 3% normal. The second subject (Subject 6) in the high dose cohort had a rise in liver enzymes 62 days post gene transfer to the upper range of normal and a drop in F.IX levels to 5%. Treatment with prednisolone returned liver enzymes levels back to baseline and F.IX levels have returned to 8–12%. Both subjects in the high dose cohort had expansion of capsid specific T cells. To date there have been no indications of any immune responses against F.IX in vector treated subjects. Interestingly, similar expression levels of F.IX and transaminitis were also observed at the same dose of 2×10^{12} vg/kg in the AAV2 hF.IX trial [8] which suggests that this dose is a threshold for capsid antigen presentation on hepatocytes. The similar expression of F.IX obtained with both vectors may reflect the fact that the ssAAV2 hF.IX vector was delivered by hepatic artery, while the scAAV8 hF.IX vector was administered by peripheral vein (Table 1). The benefits of increasing to a higher vector dose will need to be weighed against the risks of exacerbating an already existing capsid specific T cell response through innate immune response induction [88] and potential impacts on immune responses against the F.IX protein.

Hepatic AAV Gene Therapy for Hemophilia A

Similar to hemophilia B, F.VIII knock-out mice were generated (by targeted deletion of exon 16 or 17) [89] and three spontaneous canine hemophilia A models are being maintained [90–94]. In two of the canine models, the underlying mutation was identified as an inversion of exons 1–22, similar to a common mutation in humans [95]. Although hemophilia A is more common than hemophilia B, progress on developing an AAV vector has been limited based on several factors including cDNA length exceeding AAV packaging capacity, poor expression and secretion of F.VIII protein, and low specific activity of human F.VIII in animal models. The F.VIII protein contains multiple domains including a large B domain that can be deleted with the resulting B domain deleted F.VIII (BDD-F.VIII) exhibiting no loss in activity as compared to full length F.VIII [96]. The BBD-F.VIII cDNA length of 4.4kb has allowed for successful packaging into AAV vectors [97,98]. Another adaption was to split the cDNA for F.VIII into two vectors expressing the heavy and light chain [99–102]. One disadvantage of this approach is that secretion of light chain (LC) is 1–2 logs higher than of heavy chain (HC). While it is possible to try and balance this by adjusting the relative LC and HC vector doses, Chen et al. described a modified HC with up to four fold improved secretion in mice [102]. Yan et al. also describe the splitting of a gene between two vectors in a processed dubbed trans-splicing that allows for expressing a cDNA larger than 5kb [103], which can also be exploited for expression of F.VIII [104]. While functional, dual vector strategies are generally less efficient as the chance for the same cell to be transduced by both vectors at an optimal ratio is low.

Burton et al. first described AAV2 dual chain hF.VIII vectors delivered via the portal vein to wild type C57BL/6 mice reaching levels of 200–400 ng/ml of biologically active hF.VIII

protein [100]. Using a similar approach in hemophilia A mice, AAV2 dual chain hF.VIII or cF.VIII vectors resulted in phenotypic correction [105]. Sarkar et al. using an AAV2 vector with a synthetic albumin promoter driving BDD-murine F.VIII (mF.VIII) expression, compared different routes of delivery in hemophilia A mice and observed partial correction up to 9 months without inhibitor development [106]. Utilizing AAV8 and either a dual chain canine F.VIII or BDD canine F.VIII Sarkar et al. were able to restore 100% F.VIII activity in hemophilia A mice [101]. Mah et al. reported up to 31% of normal mF.VIII when using an AAV2 dual chain mF.VIII vector with intravenous delivery [107]. Scallan et al. reported sustained 2–4% normal levels (> 14 month) in hemophilia A dogs using intra hepatic delivery of an AAV2 TTR BDD cF.VIII vector [108]. Jiang et al. compared AAV2, AAV6, and AAV8 serotypes expressing BDD-cF.VIII (from a transthyretin-derived, TTR, promoter) in murine and canine hemophilia A models [109]. Interestingly, a large fraction of hemophilia A mice receiving high dose AAV6 and AAV8 vectors developed inhibitors to cF.VIII, while in contrast to mice, hemophilia A dogs had long-term stable expression with similar liver transduction efficiencies between the three different serotypes [109]. Sarkar et al. found a similar discordance between murine and canine gene transfer of AAV8 and AAV9 dual chain cF.VIII vectors with longterm F.VIII levels 2–2.5% of normal, and a single AAV8 treated dog with >4.5% for more than two years [110]. Ishiwata et al. showed longterm BDD cF.VIII expression in hemophilia A mice in the absence of inhibitors using an enhanced liver specific promoter [111]. Lu et al. reported complete correction in hemophilia A mice up to 8 weeks following intravenous delivery of an AAV8 CB-BDD hF.VIII vector [112]. Sabatino et al. performed a systematic study in hemophilia A dogs with peripheral vein delivery of an AAV8 BDD cF.VIII vector and portal vein delivery of AAV8 or AAV9 dual chain cF.VIII vectors [113]. Both delivery routes, serotypes, and single or dual chain F.VIII vectors led to long-term F.VIII expression, reduction in bleeding episodes, and treated dogs had no sign of long-term inhibitor formation [113].

Significant progress has been made in AAV liver gene transfer of F.VIII for treating hemophilia A in small and large animal models. What is required to translate these studies into the clinic? The major limitation from most of these studies is the use of canine F.VIII, which has been shown to not only have a higher specific activity compared to human and murine F.VIII, but is also more stable [114]. As it stands, it will be difficult to obtain regulatory approval for the delivery of a non-human gene into patients. There are several alternatives that have been shown to enhance transgene expression in ssAAV vectors including the use of tyrosine mutant capsid variants [24], the clinically approved proteasome inhibitor bortezomib for cF.VIII [82], blocking phosphorylation of FKBP52 [16,17], and the use of codon optimization which has shown to improve F.VIII expression levels in a lentiviral vector [115]. Perhaps a combination of several of the above approaches could lead to an AAV vector with suitable hF.VIII expression levels to initiate a clinical trial.

Immunological Hurdles for AAV Liver Gene Transfer - F.VIII and F.IX Inhibitors

As most initial clinical studies will be conducted in adults with hemophilia, there is a probability that subjects will either have previously developed an inhibitor, be at risk for developing an inhibitor, or may currently have an inhibitor. Since scAAV8-cohF.IX liver gene transfer has been shown to provide long-term correction in hemophilia B subjects, what are the potential risks and benefits associated with liver gene transfer to patients with existing inhibitors? To address this, Finn et al. asked the question of whether hepatic AAV gene transfer of cF.VIII could reverse pre-existing inhibitors in canine hemophilia A [116]. Using AAV8 dual chain cF.VIII vectors, they were able to demonstrate reversal of starting 3–8 BU inhibitors which initially generated a peak 4.5–12 BU following gene transfer and resolved to undetectable levels 4–5 weeks post vector treatment with measureable levels of

circulating F.VIII protein [116]. One dog with a higher starting inhibitor of 24 BU had a peak inhibitor of 216 BU three weeks post gene transfer that declined to 0.8 BU at 80 weeks post treatment [116]. All treated animals had a sharp decline in bleeding episodes following vector treatment. Although a limited number of animals were studied and starting inhibitor levels were mild, these data open the possibility for AAV liver gene transfer for hemophilia in patients with pre-existing inhibitors or with an inhibitor prone genotype. Additionally, liver gene transfer has the potential to replace expensive long-term immune tolerance induction (ITI) protocols as a means of eradicating inhibitors in hemophilia patients.

In recent years, a murine hemophilia B model was developed that not only shows high-titer inhibitor formation against F.IX protein but also IgE formation and anaphylactic reactions, similar to observation in humans with F9 gene deletions [25,117,118] Ongoing studies will determine whether hepatic AAV-F.IX gene transfer can reverse these potentially fatal responses.

NAB against AAV

Ideally, to correct the bleeding disorder early in life, gene transfer for hemophilia would occur in children. A retrospective study of pediatric hemophilia patients that are less than two years showed antibodies against AAV2 and AAV8 at 12 and 3% respectively [63], which is much lower than that found in the adult population [62]. One disadvantage of AAV delivery to young children is the potential loss of gene expression with the growth of the child. Primary exposure to an AAV vector in humans with low titer NAB has been shown to strongly induce a NAB response [8], which can block re-administration of same serotype. Several transient immune suppression protocols have been developed to allow re-administration of AAV vectors in mice and nonhuman primates [119–121] that may be adapted for human use. Unfortunately, there has been minimal progress made on how to eliminate existing NAB against AAV serotypes. With estimates ranging from 30 to 60% of individuals having neutralizing antibodies against AAV serotypes, how can these patients be treated with AAV liver gene transfer? Ironically, the impact of NAB against AAV may be of greater importance with the development of more efficient vectors to evade CD8⁺ T cell activation, in that lower vector doses may be effectively neutralized at lower antibody titers. Several approaches have been considered such as plasmapheresis or pharmacological treatments that either act to lower circulating IgG titers or to transiently deplete antibody secreting B cells with an anti-CD20 antibody. The risks of such procedures need to be assessed, particularly in the hemophilia population. Another approach involves modifying capsids to avoid neutralization. This has been explored with both site-directed mutagenesis of known neutralizing epitopes of AAV2 [122,123] and a directed evolution approach to select neutralizing resistant capsids [124]. While simply switching capsid serotypes may work in some cases [26,85] there appears to be higher incidence of NAB to capsids isolated from nonhuman primates, such as AAV8, in humans than previously suspected [62,63], thus limiting the effectiveness of swapping capsid. Since different capsids have different tissue tropism and gene transfer efficiencies, some capsids may not be suitable for this purpose.

Safety Concerns for AAV Liver Gene Transfer

A major concern for gene transfer studies in humans is vertical transmission to germline cells. Studies conducted in male animal models including mice, rat, dog, and rabbit were conducted to assess the risk of germline transmission from intramuscular and intravascular delivery of an AAV2-hF.IX vector. Vector shedding into semen that was rapidly cleared with no evidence of gene transfer to germline cells was observed independent of delivery route [125,126]. An additional study in rabbits assessed the risk of a different AAV serotype, AAV8, which is currently being used in a clinical trial for hemophilia B, and

showed a similar low risk of germline transmission as found with AAV2 [127]. Additionally, both human trials with AAV2 hF.IX vectors [7,8] have not shown any indication of germline transmission, validating the results obtained with the rabbit model.

Viral vector integration has been linked to insertional mutagenesis in three clinical trials of gamma retroviral vector gene transfer to human hematopoietic stem cells [128–131]. Although AAV vectors are predominantly non-integrating and remain as episomes, it has been demonstrated that integration occurs in the liver at a low frequency [132] and may pose a risk for insertional mutagenesis. A study conducted by Donsante et al. observed an increased incidence of hepatocellular carcinoma (HCC) in newborn mice given AAV liver gene transfer [133]. A follow-up study identified AAV integration sites in chromosome 12 from four liver tumors and suggested that dysregulation of snoRNAs and miRNAs from vector integration resulted in the development of HCC [134]. In contrast to these findings, multiple long-term studies in mice [135,136], canines [40,113], and to date humans [8] injected with AAV vectors have no indication of increased risk of HCC from AAV insertional mutagenesis. Although animal models seem to indicate there is no risk for HCC, it would be warranted to perform long-term follow-up studies on all human trials conducted with AAV as prior experience has shown with gamma retroviral vectors and AAV lack of a response in an animal model does not necessitate lack of response in humans.

Summary and Conclusions

Ample pre-clinical successes have been reported with AAV-F. VIII and -F.IX gene transfer vectors in murine and canine hemophilia models. AAV liver restricted gene transfer of F.VIII and F.IX results in tolerance mediated by induction of regulatory T cells. Studies in NHPs have helped to better understand potential immune responses against vector and transgene in the context of prior exposure to AAV from natural infection (both mice and dogs are not naturally infected with AAV) and have been instrumental in developing immune suppression protocols.

An initial clinical trial with AAV2 F.IX resulted in transient correction of disease in a subject at a dose of 2×10^{12} vg/kg. Of note, none of the treated patients developed a F.IX specific immune response, but instead two patients had an activated a memory CD8⁺ T cell response (most likely from previous exposure to AAV from natural infection) that resulted in the elimination of transduced hepatocytes returning F.IX expression to baseline levels. First long-term correction of hemophilia B in patients has been accomplished using an scAAV8 LP-1 cohF.IX vector. Although there was indication of an activated capsid specific CD8⁺ T cells and a mild rise in liver transaminases, rapid treatment with prednisolone resolved the transaminitis without significant loss to F.IX expression levels. It is unclear if increasing vector doses may reach a threshold for activation of an innate response and CD8⁺ T cell capsid response and what, if any potential consequences this would entail for immune responses to vector and F.IX.

The success of the scAAV8 LP-1 cohF.IX liver gene transfer trial will hopefully not only lead to a permanent cure for hemophilia B, but pave the way for the development of AAV liver gene transfer-based therapies for hemophilia A, lysosomal storage disorders, and inherited metabolic diseases.

Acknowledgments

This work was supported by NIH grants P01 HL078810, R01 HL097088, and R01 AI51390.

References

1. Wu Z, Asokan A, Samulski RJ. Adeno-associated virus serotypes: vector toolkit for human gene therapy. *Mol Ther.* 2006; 14:316–327. [PubMed: 16824801]
2. Zaiss AK, Liu Q, Bowen GP, Wong NC, Bartlett JS, et al. Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors. *J Virol.* 2002; 76:4580–4590. [PubMed: 11932423]
3. McCaffrey AP, Fawcett P, Nakai H, McCaffrey RL, Ehrhardt A, et al. The host response to adenovirus, helper-dependent adenovirus, and adeno-associated virus in mouse liver. *Mol Ther.* 2008; 16:931–941. [PubMed: 18388926]
4. Zaiss AK, Muruve DA. Immune responses to adeno-associated virus vectors. *Curr Gene Ther.* 2005; 5:323–331. [PubMed: 15975009]
5. Duan D, Sharma P, Yang J, Yue Y, Dudus L, et al. Circular intermediates of recombinant adeno-associated virus have defined structural characteristics responsible for long-term episomal persistence in muscle tissue. *J Virol.* 1998; 72:8568–8577. [PubMed: 9765395]
6. Nakai H, Yant SR, Storm TA, Fuess S, Meuse L, et al. Extrachromosomal recombinant adeno-associated virus vector genomes are primarily responsible for stable liver transduction *in vivo*. *J Virol.* 2001; 75:6969–6976. [PubMed: 11435577]
7. Manno CS, Chew AJ, Hutchison S, Larson PJ, Herzog RW, et al. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. *Blood.* 2003; 101:2963–2972. [PubMed: 12515715]
8. Manno CS, Pierce GF, Arruda VR, Glader B, Ragni M, et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. *Nat Med.* 2006; 12:342–347. [PubMed: 16474400]
9. Snyder RO, Miao CH, Patijn GA, Spratt SK, Danos O, et al. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors. *Nat Genet.* 1997; 16:270–276. [PubMed: 9207793]
10. Miao CH, Snyder RO, Schowalter DB, Patijn GA, Donahue B, et al. The kinetics of rAAV integration in the liver. *Nat Genet.* 1998; 19:13–15. [PubMed: 9590280]
11. Ponnazhagan S, Mukherjee P, Yoder MC, Wang XS, Zhou SZ, et al. Adeno-associated virus 2-mediated gene transfer *in vivo*: organ-tropism and expression of transduced sequences in mice. *Gene.* 1997; 190:203–210. [PubMed: 9185868]
12. Fisher KJ, Gao GP, Weitzman MD, DeMatteo R, Burda JF, et al. Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis. *J Virol.* 1996; 70:520–532. [PubMed: 8523565]
13. Ferrari FK, Samulski T, Shenk T, Samulski RJ. Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors. *J Virol.* 1996; 70:3227–3234. [PubMed: 8627803]
14. Qing K, Hansen J, Weigel-Kelley KA, Tan M, Zhou S, et al. Adeno-associated virus type 2-mediated gene transfer: role of cellular FKBP52 protein in transgene expression. *J Virol.* 2001; 75:8968–8976. [PubMed: 11533160]
15. Mah C, Qing K, Khuntirat B, Ponnazhagan S, Wang XS, et al. Adeno-associated virus type 2-mediated gene transfer: role of epidermal growth factor receptor protein tyrosine kinase in transgene expression. *J Virol.* 1998; 72:9835–9843. [PubMed: 9811719]
16. Qing K, Li W, Zhong L, Tan M, Hansen J, et al. Adeno-associated virus type 2-mediated gene transfer: role of cellular T-cell protein tyrosine phosphatase in transgene expression in established cell lines *in vitro* and transgenic mice *in vivo*. *J Virol.* 2003; 77:2741–2746. [PubMed: 12552015]
17. Zhao W, Wu J, Zhong L, Srivastava A. Adeno-associated virus 2-mediated gene transfer: role of a cellular serine/threonine protein phosphatase in augmenting transduction efficiency. *Gene Ther.* 2007; 14:545–550. [PubMed: 17122803]
18. McCarty DM, Monahan PE, Samulski RJ. Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis. *Gene Ther.* 2001; 8:1248–1254. [PubMed: 11509958]

19. McCarty DM, Fu H, Monahan PE, Toulson CE, Naik P, et al. Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction *in vivo*. *Gene Ther.* 2003; 10:2112–2118. [PubMed: 14625565]
20. Wang Z, Ma HI, Li J, Sun L, Zhang J, et al. Rapid and highly efficient transduction by double-stranded adeno-associated virus vectors *in vitro* and *in vivo*. *Gene Ther.* 2003; 10:2105–2111. [PubMed: 14625564]
21. Hansen J, Qing K, Kwon HJ, Mah C, Srivastava A. Impaired intracellular trafficking of adeno-associated virus type 2 vectors limits efficient transduction of murine fibroblasts. *J Virol.* 2000; 74:992–996. [PubMed: 10623762]
22. Duan D, Yue Y, Yan Z, Yang J, Engelhardt JF. Endosomal processing limits gene transfer to polarized airway epithelia by adeno-associated virus. *J Clin Invest.* 2000; 105:1573–1587. [PubMed: 10841516]
23. Zhong L, Zhao W, Wu J, Li B, Zolotukhin S, et al. A dual role of EGFR protein tyrosine kinase signaling in ubiquitination of AAV2 capsids and viral second-strand DNA synthesis. *Mol Ther.* 2007; 15:1323–1330. [PubMed: 17440440]
24. Zhong L, Li B, Mah CS, Govindasamy L, Agbandje-McKenna M, et al. Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses. *Proc Natl Acad Sci U S A.* 2008; 105:7827–7832. [PubMed: 18511559]
25. Markusic DM, Herzog RW, Aslanidi GV, Hoffman BE, Li B, et al. High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. *Mol Ther.* 2010; 18:2048–2056. [PubMed: 20736929]
26. Gao GP, Alvira MR, Wang L, Calcedo R, Johnston J, et al. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. *Proc Natl Acad Sci U S A.* 2002; 99:11854–11859. [PubMed: 12192090]
27. Nakai H, Fuess S, Storm TA, Muramatsu S, Nara Y, et al. Unrestricted hepatocyte transduction with adeno-associated virus serotype 8 vectors in mice. *J Virol.* 2005; 79:214–224. [PubMed: 15596817]
28. Davidoff AM, Gray JT, Ng CY, Zhang Y, Zhou J, et al. Comparison of the ability of adeno-associated viral vectors pseudotyped with serotype 2, 5, and 8 capsid proteins to mediate efficient transduction of the liver in murine and nonhuman primate models. *Mol Ther.* 2005; 11:875–888. [PubMed: 15922958]
29. Thomas CE, Storm TA, Huang Z, Kay MA. Rapid uncoating of vector genomes is the key to efficient liver transduction with pseudotyped adeno-associated virus vectors. *J Virol.* 2004; 78:3110–3122. [PubMed: 14990730]
30. Lin HF, Maeda N, Smithies O, Straight DL, Stafford DW. A coagulation factor IX-deficient mouse model for human hemophilia B. *Blood.* 1997; 90:3962–3966. [PubMed: 9354664]
31. Wang L, Zoppe M, Hackeng TM, Griffin JH, Lee KF, et al. A factor IX-deficient mouse model for hemophilia B gene therapy. *Proc Natl Acad Sci U S A.* 1997; 94:11563–11566. [PubMed: 9326649]
32. Kundu RK, Sangiorgi F, Wu LY, Kurachi K, Anderson WF, et al. Targeted inactivation of the coagulation factor IX gene causes hemophilia B in mice. *Blood.* 1998; 92:168–174. [PubMed: 9639513]
33. Evans JP, Brinkhous KM, Brayer GD, Reisner HM, High KA. Canine hemophilia B resulting from a point mutation with unusual consequences. *Proc Natl Acad Sci U S A.* 1989; 86:10095–10099. [PubMed: 2481310]
34. Mauser AE, Whitlark J, Whitney KM, Lothrop CD Jr. A deletion mutation causes hemophilia B in Lhasa Apso dogs. *Blood.* 1996; 88:3451–3455. [PubMed: 8896410]
35. Nakai H, Herzog RW, Hagstrom JN, Walter J, Kung SH, et al. Adeno-associated viral vector-mediated gene transfer of human blood coagulation factor IX into mouse liver. *Blood.* 1998; 91:4600–4607. [PubMed: 9616156]
36. Herzog RW, Yang EY, Couto LB, Hagstrom JN, Elwell D, et al. Longterm correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector. *Nat Med.* 1999; 5:56–63. [PubMed: 9883840]

37. Wang L, Takabe K, Bidlingmaier SM, III CR, Verma IM. Sustained correction of bleeding disorder in hemophilia B mice by gene therapy. *Proc Natl Acad Sci U S A*. 1999; 96:3906–3910. [PubMed: 10097136]
38. Wang L, Nichols TC, Read MS, Bellinger DA, Verma IM. Sustained expression of therapeutic level of factor IX in hemophilia B dogs by AAV-mediated gene therapy in liver. *Mol Ther*. 2000; 1:154–158. [PubMed: 10933925]
39. Mount JD, Herzog RW, Tillson DM, Goodman SA, Robinson N, et al. Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy. *Blood*. 2002; 99:2670–2676. [PubMed: 11929752]
40. Niemeyer GP, Herzog RW, Mount J, Arruda VR, Tillson DM, et al. Longterm correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapy. *Blood*. 2009; 113:797–806. [PubMed: 18957684]
41. Nathwani AC, Davidoff A, Hanawa H, Zhou JF, Vanin EF, et al. Factors influencing *in vivo* transduction by recombinant adeno-associated viral vectors expressing the human factor IX cDNA. *Blood*. 2001; 97:1258–1265. [PubMed: 11222368]
42. Cao O, Hoffman BE, Moghimi B, Nayak S, Cooper M, et al. Impact of the underlying mutation and the route of vector administration on immune responses to factor IX in gene therapy for hemophilia B. *Mol Ther*. 2009; 17:1733–1742. [PubMed: 19603001]
43. LoDuca PA, Hoffman BE, Herzog RW. Hepatic gene transfer as a means of tolerance induction to transgene products. *Curr Gene Ther*. 2009; 9:104–114. [PubMed: 19355868]
44. Mingozzi F, Liu YL, Dobrzynski E, Kaufhold A, Liu JH, et al. Induction of immune tolerance to coagulation factor IX antigen by *in vivo* hepatic gene transfer. *J Clin Invest*. 2003; 111:1347–1356. [PubMed: 12727926]
45. Dobrzynski E, Fitzgerald JC, Cao O, Mingozzi F, Wang L, et al. Prevention of cytotoxic T lymphocyte responses to factor IX-expressing hepatocytes by gene transfer-induced regulatory T cells. *Proc Natl Acad Sci U S A*. 2006; 103:4592–4597. [PubMed: 16537361]
46. Dobrzynski E, Mingozzi F, Liu YL, Bendo E, Cao O, et al. Induction of antigen-specific CD4+ T-cell anergy and deletion by *in vivo* viral gene transfer. *Blood*. 2004; 104:969–977. [PubMed: 15105293]
47. Cao O, Dobrzynski E, Wang L, Nayak S, Mingle B, et al. Induction and role of regulatory CD4+CD25+ T cells in tolerance to the transgene product following hepatic *in vivo* gene transfer. *Blood*. 2007; 110:1132–1140. [PubMed: 17438084]
48. Breous E, Somanathan S, Vandenberghe LH, Wilson JM. Hepatic regulatory T cells and Kupffer cells are crucial mediators of systemic T cell tolerance to antigens targeting murine liver. *Hepatology*. 2009; 50:612–621. [PubMed: 19575456]
49. Martino AT, Nayak S, Hoffman BE, Cooper M, Liao G, et al. Tolerance induction to cytoplasmic beta-galactosidase by hepatic AAV gene transfer: implications for antigen presentation and immunotoxicity. *PLoS One*. 2009; 4:e6376. [PubMed: 19652717]
50. Annoni A, Brown BD, Cantore A, Sergi LS, Naldini L, et al. *In vivo* delivery of a microRNA-regulated transgene induces antigen-specific regulatory T cells and promotes immunologic tolerance. *Blood*. 2009; 114:5152–5161. [PubMed: 19794140]
51. Hoffman BE, Martino AT, Sack BK, Cao O, Liao G, et al. Nonredundant roles of IL-10 and TGF-beta in suppression of immune responses to hepatic AAV-factor IX gene transfer. *Mol Ther*. 2011; 19:1263–1272. [PubMed: 21386826]
52. Cao O, Loduca PA, Herzog RW. Role of regulatory T cells in tolerance to coagulation factors. *J Thromb Haemost*. 2009; 7(Suppl 1):88–91. [PubMed: 19630776]
53. Herzog RW. Hepatic AAV gene transfer and the immune system: friends or foes? *Mol Ther*. 2010; 18:1063–1066. [PubMed: 20514031]
54. Mays LE, Wilson JM. The complex and evolving story of T cell activation to AAV vector-encoded transgene products. *Mol Ther*. 2011; 19:16–27. [PubMed: 21119617]
55. Kay MA, Manno CS, Ragni MV, Larson PJ, Couto LB, et al. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. *Nat Genet*. 2000; 24:257–261. [PubMed: 10700178]

56. Blacklow NR, Hoggan MD, Sereno MS, Brandt CD, Kim HW, et al. A seroepidemiologic study of adenovirus-associated virus infection in infants and children. *Am J Epidemiol.* 1971; 94:359–366. [PubMed: 4329327]
57. Blacklow NR, Hoggan MD, Rowe WP. Serologic evidence for human infection with adenovirus-associated viruses. *J Natl Cancer Inst.* 1968; 40:319–327. [PubMed: 4295610]
58. Chirmule N, Probert K, Magosin S, Qian Y, Qian R, et al. Immune responses to adenovirus and adeno-associated virus in humans. *Gene Ther.* 1999; 6:1574–1583. [PubMed: 10490767]
59. Scallan CD, Jiang H, Liu T, Patarroyo-White S, Sommer JM, et al. Human immunoglobulin inhibits liver transduction by AAV vectors at low AAV2 neutralizing titers in SCID mice. *Blood.* 2006; 107:1810–1817. [PubMed: 16249376]
60. Murphy SL, Li H, Zhou S, Schlachterman A, High KA. Prolonged susceptibility to antibody-mediated neutralization for adeno-associated vectors targeted to the liver. *Mol Ther.* 2008; 16:138–145. [PubMed: 17955024]
61. Hurlbut GD, Ziegler RJ, Nietupski JB, Foley JW, Woodworth LA, et al. Preexisting immunity and low expression in primates highlight translational challenges for liver-directed AAV8-mediated gene therapy. *Mol Ther.* 2010; 18:1983–1994. [PubMed: 20736932]
62. Calcedo R, Vandenberghe LH, Gao G, Lin J, Wilson JM. Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. *J Infect Dis.* 2009; 199:381–390. [PubMed: 19133809]
63. Li C, Narkbunnam N, Samulski RJ, Asokan A, Hu G, et al. Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophilia. *Gene Ther.* 2011
64. Halbert CL, Miller AD, McNamara S, Emerson J, Gibson RL, et al. Prevalence of neutralizing antibodies against adeno-associated virus (AAV) types 2, 5, and 6 in cystic fibrosis and normal populations: Implications for gene therapy using AAV vectors. *Hum Gene Ther.* 2006; 17:440–447. [PubMed: 16610931]
65. Mingozi F, Maus MV, Hui DJ, Sabatino DE, Murphy SL, et al. CD8(+) T-cell responses to adeno-associated virus capsid in humans. *Nat Med.* 2007; 13:419–422. [PubMed: 17369837]
66. Pien GC, Basner-Tschakarjan E, Hui DJ, Mentlik AN, Finn JD, et al. Capsid antigen presentation flags human hepatocytes for destruction after transduction by adeno-associated viral vectors. *J Clin Invest.* 2009; 119:1688–1695. [PubMed: 19436115]
67. Herzog RW. Immune responses to AAV capsid: are mice not humans after all? *Mol Ther.* 2007; 15:649–650. [PubMed: 17372595]
68. Wang L, Figueredo J, Calcedo R, Lin J, Wilson JM. Cross-presentation of adeno-associated virus serotype 2 capsids activates cytotoxic T cells but does not render hepatocytes effective cytolytic targets. *Hum Gene Ther.* 2007; 18:185–194. [PubMed: 17324107]
69. Mays LE, Vandenberghe LH, Xiao R, Bell P, Nam HJ, et al. Adeno-associated virus capsid structure drives CD4-dependent CD8+ T cell response to vector encoded proteins. *J Immunol.* 2009; 182:6051–6060. [PubMed: 19414756]
70. Li C, Hirsch M, Asokan A, Zeithaml B, Ma H, et al. Adeno-associated virus type 2 (AAV2) capsid-specific cytotoxic T lymphocytes eliminate only vector-transduced cells coexpressing the AAV2 capsid *in vivo*. *J Virol.* 2007; 81:7540–7547. [PubMed: 17475652]
71. Lin SW, Hensley SE, Tatsis N, Lasaro MO, Ertl HC. Recombinant adeno-associated virus vectors induce functionally impaired transgene product-specific CD8+ T cells in mice. *J Clin Invest.* 2007; 117:3958–3970. [PubMed: 18008010]
72. Li H, Murphy SL, Giles-Davis W, Edmonson S, Xiang Z, et al. Preexisting AAV capsid-specific CD8+ T cells are unable to eliminate AAV-transduced hepatocytes. *Mol Ther.* 2007; 15:792–800. [PubMed: 17245353]
73. Li H, Lin SW, Giles-Davis W, Li Y, Zhou D, et al. A preclinical animal model to assess the effect of pre-existing immunity on AAV-mediated gene transfer. *Mol Ther.* 2009; 17:1215–1224. [PubMed: 19367258]
74. Li H, Tuyishime S, Wu TL, Giles-Davis W, Zhou D, et al. Adeno-associated virus vectors serotype 2 induce prolonged proliferation of capsid-specific CD8+ T cells in mice. *Mol Ther.* 2011; 19:536–546. [PubMed: 21157435]

75. Gao G, Wang Q, Calcedo R, Mays L, Bell P, et al. Adeno-associated virus-mediated gene transfer to nonhuman primate liver can elicit destructive transgene-specific T cell responses. *Hum Gene Ther.* 2009; 20:930–942. [PubMed: 19441963]
76. Li H, Lasaro MO, Jia B, Lin SW, Haut LH, et al. Capsid-specific T-cell Responses to Natural Infections With Adeno-associated Viruses in Humans Differ From Those of Nonhuman Primates. *Mol Ther.* 2011; 19:2021–2030. [PubMed: 21587208]
77. Li C, Goudy K, Hirsch M, Asokan A, Fan Y, et al. Cellular immune response to cryptic epitopes during therapeutic gene transfer. *Proc Natl Acad Sci U S A.* 2009; 106:10770–10774. [PubMed: 19541644]
78. Hauck B, Murphy SL, Smith PH, Qu G, Liu X, et al. Undetectable transcription of cap in a clinical AAV vector: implications for preformed capsid in immune responses. *Mol Ther.* 2009; 17:144–152. [PubMed: 18941440]
79. Jiang H, Couto LB, Patarroyo-White S, Liu T, Nagy D, et al. Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy. *Blood.* 2006; 108:3321–3328. [PubMed: 16868252]
80. Mingozzi F, Hasbrouck NC, Basner-Tschakarjan E, Edmonson SA, Hui DJ, et al. Modulation of tolerance to the transgene product in a nonhuman primate model of AAV-mediated gene transfer to liver. *Blood.* 2007; 110:2334–2341. [PubMed: 17609423]
81. Finn JD, Hui D, Downey HD, Dunn D, Pien GC, et al. Proteasome inhibitors decrease AAV2 capsid derived peptide epitope presentation on MHC class I following transduction. *Mol Ther.* 2010; 18:135–142. [PubMed: 19904235]
82. Monahan PE, Lothrop CD, Sun J, Hirsch ML, Kafri T, et al. Proteasome Inhibitors Enhance Gene Delivery by AAV Virus Vectors Expressing Large Genomes in Hemophilia Mouse and Dog Models: A Strategy for Broad Clinical Application. *Mol Ther.* 2010; 18:1907–1916. [PubMed: 20700109]
83. Cooper M, Nayak S, Hoffman BE, Terhorst C, Cao O, et al. Improved Induction of Immune Tolerance to Factor IX by Hepatic AAV-8 Gene Transfer. *Hum Gene Ther.* 2009; 20:767–776. [PubMed: 19309290]
84. Nathwani AC, Gray JT, Ng CY, Zhou J, Spence Y, et al. Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver. *Blood.* 2006; 107:2653–2661. [PubMed: 16322469]
85. Nathwani AC, Gray JT, McIntosh J, Ng CY, Zhou J, et al. Safe and efficient transduction of the liver after peripheral vein infusion of self-complementary AAV vector results in stable therapeutic expression of human FIX in nonhuman primates. *Blood.* 2007; 109:1414–1421. [PubMed: 17090654]
86. Nathwani AC, Rosales C, McIntosh J, Rastegarlar G, Nathwani D, et al. Long-term safety and efficacy following systemic administration of a self-complementary AAV vector encoding human FIX pseudotyped with serotype 5 and 8 capsid proteins. *Mol Ther.* 2011; 19:876–885. [PubMed: 21245849]
87. Nathwani AC, Tuddenham EG, Rangarajan S, Rosales C, McIntosh J, et al. Adenovirus-Associated Virus Vector-Mediated Gene Transfer in Hemophilia B. *N Engl J Med.* 2011; 365:2357–2365. [PubMed: 22149959]
88. Martino AT, Suzuki M, Markusic DM, Zolotukhin I, Ryals RC, et al. The genome of self-complementary adeno-associated viral vectors increases Toll-like receptor 9-dependent innate immune responses in the liver. *Blood.* 2011; 117:6459–6468. [PubMed: 21474674]
89. Bi L, Lawler AM, Antonarakis SE, High KA, Gearhart JD, et al. Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A. *Nat Genet.* 1995; 10:119–121. [PubMed: 7647782]
90. Graham JB, Buckwalter JA, et al. Canine hemophilia; observations on the course, the clotting anomaly, and the effect of blood transfusions. *J Exp Med.* 1949; 90:97–111. [PubMed: 18136192]
91. Giles AR, Tinlin S, Greenwood R. A canine model of hemophilic (factor VIII:C deficiency) bleeding. *Blood.* 1982; 60:727–730. [PubMed: 6809076]

92. Hough C, Kamisue S, Cameron C, Notley C, Tinlin S, et al. Aberrant splicing and premature termination of transcription of the FVIII gene as a cause of severe canine hemophilia A: similarities with the intron 22 inversion mutation in human hemophilia. *Thromb Haemost.* 2002; 87:659–665. [PubMed: 12008949]
93. Lozier JN, Dutra A, Pak E, Zhou N, Zheng Z, et al. The Chapel Hill hemophilia A dog colony exhibits a factor VIII gene inversion. *Proc Natl Acad Sci U S A.* 2002; 99:12991–12996. [PubMed: 12242334]
94. Connelly S, Mount J, Mauser A, Gardner JM, Kaleko M, et al. Complete short-term correction of canine hemophilia A by *in vivo* gene therapy. *Blood.* 1996; 88:3846–3853. [PubMed: 8916949]
95. Nichols TC, Dillow AM, Franck HW, Merricks EP, Raymer RA, et al. Protein replacement therapy and gene transfer in canine models of hemophilia A, hemophilia B, von willebrand disease, and factor VII deficiency. *ILAR J.* 2009; 50:144–167. [PubMed: 19293459]
96. Pittman DD, Alderman EM, Tomkinson KN, Wang JH, Giles AR, et al. Biochemical, immunological, and *in vivo* functional characterization of B-domain-deleted factor VIII. *Blood.* 1993; 81:2925–2935. [PubMed: 8499631]
97. Gnatenko DV, Saenko EL, Jesty J, Cao LX, Hearing P, et al. Human factor VIII can be packaged and functionally expressed in an adeno-associated virus background: applicability to haemophilia A gene therapy. *Br J Haematol.* 1999; 104:27–36. [PubMed: 10027708]
98. Chao H, Mao L, Bruce AT, Walsh CE. Sustained expression of human factor VIII in mice using a parvovirus-based vector. *Blood.* 2000; 95:1594–1599. [PubMed: 10688813]
99. Chen L, Zhu F, Li J, Lu H, Jiang H, et al. The enhancing effects of the light chain on heavy chain secretion in split delivery of factor VIII gene. *Mol Ther.* 2007; 15:1856–1862. [PubMed: 17653101]
100. Burton M, Nakai H, Colosi P, Cunningham J, Mitchell R, et al. Coexpression of factor VIII heavy and light chain adeno-associated viral vectors produces biologically active protein. *Proc Natl Acad Sci U S A.* 1999; 96:12725–12730. [PubMed: 10535990]
101. Sarkar R, Tetreault R, Gao G, Wang L, Bell P, et al. Total correction of hemophilia A mice with canine FVIII using an AAV 8 serotype. *Blood.* 2004; 103:1253–1260. [PubMed: 14551134]
102. Chen L, Lu H, Wang J, Sarkar R, Yang X, et al. Enhanced factor VIII heavy chain for gene therapy of hemophilia A. *Mol Ther.* 2009; 17:417–424. [PubMed: 19127250]
103. Yan Z, Zhang Y, Duan D, Engelhardt JF. Trans-splicing vectors expand the utility of adeno-associated virus for gene therapy. *Proc Natl Acad Sci U S A.* 2000; 97:6716–6721. [PubMed: 10841568]
104. Chao H, Sun L, Bruce A, Xiao X, Walsh CE. Expression of human factor VIII by splicing between dimerized AAV vectors. *Mol Ther.* 2002; 5:716–722. [PubMed: 12027555]
105. Scallan CD, Liu T, Parker AE, Patarroyo-White SL, Chen H, et al. Phenotypic correction of a mouse model of hemophilia A using AAV2 vectors encoding the heavy and light chains of FVIII. *Blood.* 2003; 102:3919–3926. [PubMed: 12893764]
106. Sarkar R, Xiao W, Kazazian HH Jr. A single adeno-associated virus (AAV)-murine factor VIII vector partially corrects the hemophilia A phenotype. *J Thromb Haemost.* 2003; 1:220–226. [PubMed: 12871492]
107. Mah C, Sarkar R, Zolotukhin I, Schleissing M, Xiao X, et al. Dual vectors expressing murine factor VIII result in sustained correction of hemophilia A mice. *Hum Gene Ther.* 2003; 14:143–152. [PubMed: 12614565]
108. Scallan CD, Lillicrap D, Jiang H, Qian X, Patarroyo-White SL, et al. Sustained phenotypic correction of canine hemophilia A using an adeno-associated viral vector. *Blood.* 2003; 102:2031–2037. [PubMed: 12738670]
109. Jiang H, Lillicrap D, Patarroyo-White S, Liu T, Qian X, et al. Multiyear therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A mice and dogs. *Blood.* 2006; 108:107–115. [PubMed: 16522813]
110. Sarkar R, Mucci M, Addya S, Tetreault R, Bellinger DA, et al. Long-term efficacy of adeno-associated virus serotypes 8 and 9 in hemophilia a dogs and mice. *Hum Gene Ther.* 2006; 17:427–439. [PubMed: 16610930]

111. Ishiwata A, Mimuro J, Mizukami H, Kashiwakura Y, Takano K, et al. Liver-restricted expression of the canine factor VIII gene facilitates prevention of inhibitor formation in factor VIII-deficient mice. *J Gene Med*. 2009; 11:1020–1029. [PubMed: 19757487]
112. Lu H, Chen L, Wang J, Huack B, Sarkar R, et al. Complete correction of hemophilia A with adeno-associated viral vectors containing a full-size expression cassette. *Hum Gene Ther*. 2008; 19:648–654. [PubMed: 18500941]
113. Sabatino DE, Lange AM, Altynova ES, Sarkar R, Zhou S, et al. Efficacy and safety of long-term prophylaxis in severe hemophilia A dogs following liver gene therapy using AAV vectors. *Mol Ther*. 2011; 19:442–449. [PubMed: 21081906]
114. Sabatino DE, Freguia CF, Toso R, Santos A, Merricks EP, et al. Recombinant canine B-domain-deleted FVIII exhibits high specific activity and is safe in the canine hemophilia A model. *Blood*. 2009; 114:4562–4565. [PubMed: 19770361]
115. Ward NJ, Buckley SM, Waddington SN, Vandendriessche T, Chuah MK, et al. Codon optimization of human factor VIII cDNAs leads to high-level expression. *Blood*. 2011; 117:798–807. [PubMed: 21041718]
116. Finn JD, Ozelo MC, Sabatino DE, Franck HW, Merricks EP, et al. Eradication of neutralizing antibodies to factor VIII in canine hemophilia A after liver gene therapy. *Blood*. 2010; 116:5842–5848. [PubMed: 20876851]
117. Verma D, Moghimi B, LoDuca PA, Singh HD, Hoffman BE, et al. Oral delivery of bioencapsulated coagulation factor IX prevents inhibitor formation and fatal anaphylaxis in hemophilia B mice. *Proc Natl Acad Sci U S A*. 2010; 107:7101–7106. [PubMed: 20351275]
118. Nayak S, Cao O, Hoffman BE, Cooper M, Zhou S, et al. Prophylactic immune tolerance induced by changing the ratio of antigen-specific effector to regulatory T cells. *J Thromb Haemost*. 2009; 7:1523–1532. [PubMed: 19583824]
119. Halbert CL, Standaert TA, Wilson CB, Miller AD. Successful readministration of adeno-associated virus vectors to the mouse lung requires transient immunosuppression during the initial exposure. *J Virol*. 1998; 72:9795–9805. [PubMed: 9811715]
120. Chirmule N, Xiao W, Truneh A, Schnell MA, Hughes JV, et al. Humoral immunity to adeno-associated virus type 2 vectors following administration to murine and nonhuman primate muscle. *J Virol*. 2000; 74:2420–2425. [PubMed: 10666273]
121. McIntosh JH, Cochrane M, Cobbold S, Waldmann H, Nathwani SA, et al. Successful attenuation of humoral immunity to viral capsid and transgenic protein following AAV-mediated gene transfer with a non-depleting CD4 antibody and cyclosporine. *Gene Ther*. 2011; 19:78–85. [PubMed: 21716299]
122. Lochrie MA, Tatsuno GP, Christie B, McDonnell JW, Zhou S, et al. Mutations on the external surfaces of adeno-associated virus type 2 capsids that affect transduction and neutralization. *J Virol*. 2006; 80:821–834. [PubMed: 16378984]
123. Huttner NA, Girod A, Perabo L, Edbauer D, Kleinschmidt JA, et al. Genetic modifications of the adeno-associated virus type 2 capsid reduce the affinity and the neutralizing effects of human serum antibodies. *Gene Ther*. 2003; 10:2139–2147. [PubMed: 14625569]
124. Maheshri N, Koerber JT, Kaspar BK, Schaffer DV. Directed evolution of adeno-associated virus yields enhanced gene delivery vectors. *Nat Biotechnol*. 2006; 24:198–204. [PubMed: 16429148]
125. Arruda VR, Fields PA, Milner R, Wainwright L, De Miguel MP, et al. Lack of germline transmission of vector sequences following systemic administration of recombinant AAV-2 vector in males. *Mol Ther*. 2001; 4:586–592. [PubMed: 11735343]
126. Schuettrumpf J, Liu JH, Couto LB, Addya K, Leonard DG, et al. Inadvertent germline transmission of AAV2 vector: findings in a rabbit model correlate with those in a human clinical trial. *Mol Ther*. 2006; 13:1064–1073. [PubMed: 16631412]
127. Favaro P, Downey HD, Zhou JS, Wright JF, Hauck B, et al. Host and vector-dependent effects on the risk of germline transmission of AAV vectors. *Mol Ther*. 2009; 17:1022–1030. [PubMed: 19293773]
128. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP, Wulffraat N, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. *Science*. 2003; 302:415–419. [PubMed: 14564000]

129. Ott MG, Schmidt M, Schwarzwaelder K, Stein S, Siler U, et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. *Nat Med.* 2006; 12:401–409. [PubMed: 16582916]
130. Howe SJ, Mansour MR, Schwarzwaelder K, Bartholomae C, Hubank M, et al. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. *J Clin Invest.* 2008; 118:3143–3150. [PubMed: 18688286]
131. Stein S, Ott MG, Schultze-Strasser S, Jauch A, Burwinkel B, et al. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. *Nat Med.* 2010; 16:198–204. [PubMed: 20098431]
132. Nakai H, Iwaki Y, Kay MA, Couto LB. Isolation of recombinant adeno-associated virus vector-cellular DNA junctions from mouse liver. *J Virol.* 1999; 73:5438–5447. [PubMed: 10364291]
133. Donsante A, Vogler C, Muzyczka N, Crawford JM, Barker J, et al. Observed incidence of tumorigenesis in long-term rodent studies of rAAV vectors. *Gene Ther.* 2001; 8:1343–1346. [PubMed: 11571571]
134. Donsante A, Miller DG, Li Y, Vogler C, Brunt EM, et al. AAV vector integration sites in mouse hepatocellular carcinoma. *Science.* 2007; 317:477. [PubMed: 17656716]
135. Bell P, Moscioni AD, McCarter RJ, Wu D, Gao G, et al. Analysis of tumors arising in male B6C3F1 mice with and without AAV vector delivery to liver. *Mol Ther.* 2006; 14:34–44. [PubMed: 16682254]
136. Li H, Malani N, Hamilton SR, Schlachterman A, Bussadori G, et al. Assessing the potential for AAV vector genotoxicity in a murine model. *Blood.* 2011; 117:3311–3319. [PubMed: 21106988]

Table 1

Comparison of ssAAV2 hFIX and scAAV8 hFIX clinical trials.

ssAAV2 hF.IX						
Subject	Dose vg/kg	NAB titer ¹	Peak F.IX (%)	Sustained F.IX (%)	LFT ²	Capsid specific T cells
A	8×10 ¹⁰	N/A	<1	<1	WNL	ND
B	8×10 ¹⁰	1:2	<1	<1	WNL	ND
C	4×10 ¹¹	1:2	<1	<1	WNL	ND
D	4×10 ¹¹	1:11	<1	<1	WNL	ND
G	4×10 ¹¹	<1:2	<1	<1	< Grade 1	+
E	2×10 ¹²	1:2	11	<1	Grade 3	ND
F	2×10 ¹²	1:17	3	<1	WNL	ND
scAAV8 hF.IX						
Subject	Dose vg/kg	NAB titer relative units ³	Peak F.IX (%)	Sustained F.IX (%)	LFT ²	Capsid specific T cells
S1	2×10 ¹¹	1	2	2	WNL	-
S2	2×10 ¹¹	12	2	2	WNL	-
S3	6×10 ¹¹	37	3	1-3	WNL	+
S4	6×10 ¹¹	1	4	2-3	WNL	+
S5	2×10 ¹²	5	8	3	Grade 3	+
S6	2×10 ¹²	8	12	8-12	WNL	+

¹ reciprocal dilution anti AAV2 capsid titer,

² Liver function tests (AST/ALT)

³ anti AAV8 capsid titer

WNL: within normal limits ND: not done